StockUS listing USBIXTOTCQBHealthcareCapital Destroyer

Bioxytran Inc(BIXT) Stock Analysis | Healthcare

USD --+0.00%
Reward29Low
Risk86High
75%Data
USD —+0.00 (+0.00%) Previous close · OTCQB
Market cap 4.10M
Reward Ratingⓘ29 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ86 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BIXT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Bioxytran Inc?

, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans.

AI Brief Pro

The brief on Bioxytran Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Bioxytran Inc?

, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 4.10M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (29)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.516
Insider Activity
12M windowNo data
No insider activity data available for this ticker.